These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 27149616)

  • 1. Exploiting Genetic Interference for Antiviral Therapy.
    Tanner EJ; Kirkegaard KA; Weinberger LS
    PLoS Genet; 2016 May; 12(5):e1005986. PubMed ID: 27149616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Importin-α7 as a Therapeutic Approach against Pandemic Influenza Viruses.
    Resa-Infante P; Paterson D; Bonet J; Otte A; Oliva B; Fodor E; Gabriel G
    J Virol; 2015 Sep; 89(17):9010-20. PubMed ID: 26085167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ongoing battle against influenza: Drug-resistant influenza viruses: why fitness matters.
    Kelso A; Hurt AC
    Nat Med; 2012 Oct; 18(10):1470-1. PubMed ID: 23042350
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetic diversity among pandemic 2009 influenza viruses isolated from a transmission chain.
    Fordyce SL; Bragstad K; Pedersen SS; Jensen TG; Gahrn-Hansen B; Daniels R; Hay A; Kampmann ML; Bruhn CA; Moreno-Mayar JV; Ávila-Arcos MC; Gilbert MT; Nielsen LP
    Virol J; 2013 Apr; 10():116. PubMed ID: 23587185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virology. Helping the resistance.
    Holmes EC
    Science; 2010 Jun; 328(5983):1243-4. PubMed ID: 20522766
    [No Abstract]   [Full Text] [Related]  

  • 6. Genomic signatures and antiviral drug susceptibility profile of A(H1N1)pdm09.
    Gíria MT; Rebelo de Andrade H; Santos LA; Correia VM; Pedro SV; Santos MA
    J Clin Virol; 2012 Feb; 53(2):140-4. PubMed ID: 22177272
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Lloren KKS; Kwon JJ; Choi WS; Jeong JH; Ahn SJ; Choi YK; Baek YH; Song MS
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30602610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Permissive changes in the neuraminidase play a dominant role in improving the viral fitness of oseltamivir-resistant seasonal influenza A(H1N1) strains.
    Abed Y; Pizzorno A; Bouhy X; Boivin G
    Antiviral Res; 2015 Feb; 114():57-61. PubMed ID: 25512229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Life cycle synchronization is a viral drug resistance mechanism.
    Neagu IA; Olejarz J; Freeman M; Rosenbloom DIS; Nowak MA; Hill AL
    PLoS Comput Biol; 2018 Feb; 14(2):e1005947. PubMed ID: 29447150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolutionary analysis of human immunodeficiency virus type 1 therapies based on conditionally replicating vectors.
    Ke R; Lloyd-Smith JO
    PLoS Comput Biol; 2012; 8(10):e1002744. PubMed ID: 23133349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.
    Bloom JD; Gong LI; Baltimore D
    Science; 2010 Jun; 328(5983):1272-5. PubMed ID: 20522774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.
    Pizzorno A; Abed Y; Plante PL; Carbonneau J; Baz M; Hamelin MÈ; Corbeil J; Boivin G
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6398-405. PubMed ID: 25114143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can modulation of viral fitness represent a target for anti-HIV-1 strategies?
    Clementi M
    New Microbiol; 2004 Jul; 27(3):207-14. PubMed ID: 15460522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Naturally occurring oseltamivir resistance in influenza A].
    Madsen L; Nielsen A; Lundgren J
    Ugeskr Laeger; 2010 Aug; 172(32):2165-7. PubMed ID: 20696118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic diversity of oseltamivir-resistant influenza virus A (H1N1), Luxembourg, 2007-08.
    Gerloff NA; Kremer JR; Mossong J; Opp M; Muller CP
    Emerg Infect Dis; 2009 Sep; 15(9):1523-4. PubMed ID: 19788831
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases.
    Nijhuis M; van Maarseveen NM; Boucher CA
    Handb Exp Pharmacol; 2009; (189):299-320. PubMed ID: 19048205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community spread and late season increased incidence of oseltamivir-resistant influenza A(H1N1) viruses in Norway 2016.
    Bragstad K; Hungnes O; Litleskare I; Nyrerød HC; Dorenberg DH; Hauge SH
    Influenza Other Respir Viruses; 2019 Jul; 13(4):372-381. PubMed ID: 30834715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015.
    Tewawong N; Marathe BM; Poovorawan Y; Vongpunsawad S; Webby RJ; Govorkova EA
    PLoS One; 2018; 13(1):e0190877. PubMed ID: 29324781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Within-Host Evolution of Human Influenza Virus.
    Xue KS; Moncla LH; Bedford T; Bloom JD
    Trends Microbiol; 2018 Sep; 26(9):781-793. PubMed ID: 29534854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours.
    Inoue M; Barkham T; Leo YS; Chan KP; Chow A; Wong CW; Tze Chuen Lee R; Maurer-Stroh S; Lin R; Lin C
    Emerg Infect Dis; 2010 Oct; 16(10):1633-6. PubMed ID: 20875299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.